Publications - Page 20 sur 43 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Pneumopathies interstitielles diffuses (PID) 31/08/23
Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial.

Assassi S, Distler O, Allanore Y, Ogura T, Varga J, Vettori S, Crestani B, Voss F, Alves M, Stowasser S, Maher TM; SENSCIS trial investigators.

ACR Open Rheumatol. 2022 Oct;4(10):837-844.
Pneumopathies interstitielles diffuses (PID) 31/08/23
Progressive pulmonary fibrosis: all roads lead to Rome (but not all at the same speed).

Cottin V, Valenzuela C.

Eur Respir J. 2022 Oct 6;60(4):2201449.
Pneumopathies interstitielles diffuses (PID) 31/08/23
Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography.

Khanna D, Distler O, Cottin V, Brown KK, Chung L, Goldin JG, Matteson EL, Kazerooni EA, Walsh SL, McNitt-Gray M, Maher TM.

J Scleroderma Relat Disord. 2022 Oct;7(3):168-178.
Pneumopathies interstitielles diffuses (PID) 31/08/23
Drug-induced interstitial lung disease.

Spagnolo P, Bonniaud P, Rossi G, Sverzellati N, Cottin V.

Eur Respir J. 2022 Oct 27;60(4):2102776.
Pneumopathies interstitielles diffuses (PID) 31/08/23
Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial.

Assassi S, Distler O, Allanore Y, Ogura T, Varga J, Vettori S, Crestani B, Voss F, Alves M, Stowasser S, Maher TM; SENSCIS trial investigators.

ACR Open Rheumatol. 2022 Oct;4(10):837-844.
Pneumopathies interstitielles diffuses (PID) 31/08/23
A Risk Score to Detect Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Juge PA, Granger B, Debray MP, Ebstein E, Louis-Sidney F, Kedra J, Doyle TJ, Borie R, Constantin A, Combe B, Flipo RM, Mariette X, Vittecoq O, Saraux A, Carvajal-Alegria G, Sibilia J, Berenbaum F, Kannengiesser C, Boileau C, Sparks JA, Crestani B, Fautrel B, Dieudé P.

Arthritis Rheumatol. 2022 Nov;74(11):1755-1765.
Pneumopathies interstitielles diffuses (PID) 31/08/23
Instability of Mature ABCA3 Protein: Toward a New Classification of ABCA3 Mutations?

Onnée M, Duriez B, Simon S, Szczepaniak C, Guguin A, Epaud R, Hamouda S, Fanen P, de Becdelièvre A.

Am J Respir Cell Mol Biol. 2022 Nov;67(5):602-605.
Pneumopathies interstitielles diffuses (PID) 31/08/23
Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis.

Puéchal X, Iudici M, Perrodeau E, Bonnotte B, Lifermann F, Le Gallou T, Karras A, Blanchard-Delaunay C, Quéméneur T, Aouba A, Aumaître O, Cottin V, Hamidou M, Ruivard M, Cohen P, Mouthon L, Guillevin L, Ravaud P, Porcher R, Terrier B; French Vasculitis Study Group.

JAMA Netw Open. 2022 Nov 1;5(11):e2243799.
Pneumopathies interstitielles diffuses (PID) 31/08/23
Clinical and molecular analysis of lung cancers associated with fibrosing interstitial lung disease.

Héluain V, Prévot G, Cabarrou B, Calvayrac O, Taranchon-Clermont E, Didier A, Tabourier-Gouin S, Milia J, Mazières J.

Respir Med Res. 2022 Nov 30;83:100946.
Pneumopathies interstitielles diffuses (PID) 31/08/23
Progressive Pulmonary Fibrosis: Should the Timelines Be Taken Out of the Definition?

Cottin V, Brown KK, Flaherty KR, Wells AU.

Am J Respir Crit Care Med. 2022 Nov 15;206(10):1293-1294.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial.

Progressive pulmonary fibrosis: all roads lead to Rome (but not all at the same speed).

Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography.

Drug-induced interstitial lung disease.

Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial.

A Risk Score to Detect Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Instability of Mature ABCA3 Protein: Toward a New Classification of ABCA3 Mutations?

Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis.

Clinical and molecular analysis of lung cancers associated with fibrosing interstitial lung disease.

Progressive Pulmonary Fibrosis: Should the Timelines Be Taken Out of the Definition?